4 notable presentations from ASH 2025
MD Anderson researchers are working diligently to transform our understanding of blood cancers and bring the latest cutting-edge therapies to our patients. At the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition, they are sharing their latest research with colleagues from across the globe.
Here are four of their latest advances that are being presented at ASH 2025.
1. Targeted combinations for patients...
5 notable presentations from ESMO 2025
The European Society for Medical Oncology (ESMO) Congress brings together international experts for collaborative discussions on every area...
4 things I learned from my radiation oncology training at MD Anderson
As a radiation oncologist and physician-scientist, I spend my days caring for patients and running a lab dedicated to understanding the biology...
A personal calling guides postdoctoral fellow to research tumor evolution in breast cancer
For postdoctoral fellow Rachel Dittmar, Ph.D., cancer research is more than just business. It’s personal.
Having lost her grandmother to metastatic breast cancer and her mother to duodenal cancer – both died at age 53 – Dittmar chose to focus her postdoctoral research on studying tumor evolution. She works in the Navin Lab at MD Anderson under the guidance and mentorship of Nicholas Navin, Ph.D., chair of Systems Biology.  ...
Sense of urgency fuels collaboration for researcher
Jlenia Guarnerio, Ph.D., feels a sense of urgency when it comes to the work she and her fellow researchers at MD Anderson do. ...
What are neutrophils?
If you’ve ever looked at the results of a blood test, you may have noticed a neutrophil count. Neutrophils are a common type of white blood...
Using math to answer cancer’s biggest questions
One of the most important parts of science is asking the right questions. As an engineer trying to break into medical research, Joseph Butner...
Dermatologist: How to deal with targeted therapy-related skin rashes
EGFR inhibitors are a class of targeted therapy used to treat several cancers, including colorectal cancer.
About 80% of patients...
What causes chemobrain? New insights
Chemobrain is a term used to describe the changes in cognitive abilities that some patients with cancer may experience, such as:
Fogginess...
5 emerging therapies presented at ASCO 2025
Every year, the American Society of Clinical Oncology Annual Meeting provides a platform for sharing exciting new cancer therapies...